ArticleCancer science2026
TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is an extremely aggressive type of cancer with a poor prognosis and is often associated with amplification of chromosome 8q. Tonsoku-like DNA repair protein (TONSL) gene, located on 8q, plays a role in repairing DNA double-strand breaks. However, its functional relevance in HCC is not yet fully understood. In this study, we investigated the biological significance of TONSL in HCC progression. Analyses of public datasets and clinical specimens revealed that TONSL expression was markedly elevated in tumor tissues. TONSL levels showed a positive correlation with copy number variation and high levels were significantly associated with unfavorable patient outcomes. Functional assays demonstrated that TONSL knockout substantially reduced cell growth and increased apoptosis. Mechanistically, loss of TONSL impaired the recruitment of RAD51 to DNA damage sites, resulting in defective homologous recombination repair and enhanced apoptotic activity. Furthermore, TONSL-knockout HCC cells showed increased sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitor. In a xenograft model, tumors generated from TONSL-knockout cells exhibited significantly reduced growth, underscoring the importance of TONSL in promoting HCC progression. Collectively, these findings indicate that TONSL facilitates HCC development by supporting RAD51-mediated DNA repair and suppressing apoptosis, and its elevated expression serves as a marker of poor prognosis. Thus, TONSL represents a promising biomarker of tumor aggressiveness and a potential therapeutic target in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.